Management tracks: Vertex taps Bozic as CMO; plus Nektar, Sangamo, Ascletis, Neurocrine, Neovacs, Dyne, Avidity, Pulmotect, Adaptimmune and 4BIO

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said SVP and Head of Global Clinical Development Carmen Bozic will become EVP, global medicines development and medical affairs. She will take on the additional role of CMO on April 1 when Reshma Kewalramani leaves the position to succeed Jeffrey Leiden as president and CEO. Leiden, who announced his plans to step down in July, will become executive chairman. He has served as CEO since 2012, steering the company through the launches of its three cystic fibrosis drugs. The fourth therapy, its triple combo, is under FDA Priority Review with a PDUFA date of March 19 (see "As Vertex Broadens Remit, Leiden Handing Baton to Kewalramani").

The company also said SVP, Global Regulatory Affairs Nia Tatsis will become SVP, chief regulatory officer...